Association of periodic limb movements during sleep and tinnitus in humans

Sheng-Wei Hwang1,6, Yia-Chi Chu1,6, Shang-Rung Hwang2 & Juen-Haur Hwang3,4,5*

Both of periodic limb movements during sleep (PLMS) and tinnitus were related with dopaminergic system dysfunction. However, it was still unclear whether PLMS, one kind of sleep disturbances, was associated with chronic tinnitus or not. Thus, we aimed to investigate this issue in humans. Clinical and overnight polysomnographic data of 2849 adults from a community hospital during Nov. 2011 to Jun 2017 in Taiwan was collected retrospectively. The association of PLMS and chronic tinnitus was analyzed by Student’s t-test, Pearson’s Chi-Square test, and multivariate logistic regression. The results showed that the mean age was 50.6 years old (standard deviation, SD = 13.3, range = 18~91) for all subjects. There were 1886 subjects without tinnitus and 963 subjects with tinnitus in this study. The PLMS was not significantly different between subjects without tinnitus (mean = 1.0/h, SD = 3.5/h) and subjects with tinnitus mean = 1.1/h, SD = 3.4/h) by Student’s t-test. The severity of PLMS was not significantly between non-tinnitus and tinnitus subjects by Pearson’s Chi-Square test. Multivariate logistic regression also showed that PLMS was not significantly associated with tinnitus after adjusting age, sex, subjective hearing loss, Parkinson’s disease, and insomnia. In conclusion, PLMS was not associated with chronic tinnitus in humans.

Tinnitus is a phantom auditory perception. There were many types of tinnitus, for example auditory tinnitus, somatic tinnitus, vascular origin tinnitus, muscular origin tinnitus, etc. And, the prevalence of tinnitus depends on the type and/or definition for it. A nationwide survey of South Korea reported that the prevalence of any tinnitus was 20.7% among adults aged 20 to 98 years1. The prevalence of all types of tinnitus was higher in women than in men, and it increased with age1. The contributing factors and/or etiologies of tinnitus were numerous, including hearing impairment, cardiometabolic disorders, sleep disturbances and sleep apnea, migraine, and non-migraine headache, etc.2–4. And, tinnitus often comorbid with other diseases, such as anxiety, depression, brain tumors or stroke, and some symptoms including irritability, inability to concentration, and sleep disturbances5–7.

Dysfunction in the cochlea, and neural reorganization in the auditory and non-auditory cortices have been reported to be associated with auditory tinnitus8. In addition to neuroinflammation and/or oxidative stress damages9–13, increased expression of N-methyl D-aspartate (NMDA) receptor (NR) gene14, decreased γ-aminobutyric acid (GABA) receptor (GR) and cannabinoid receptor genes were found in the cochlea and some brain areas9,15. Increased expression of K+–Cl− cotransporter (KCC2) gene was also found in salicylate-induced tinnitus16. Besides, dysfunction of dopaminergic system was reported to be related with tinnitus formation17,18. On the other hand, the pathophysiology of periodic limb movements during sleep (PLMS) was reported to be related with dysfunction of dopaminergic system and/or calcium channels. And, dopamine agonists and α2δ calcium channel ligands are considered first-line treatments for PLMS and other sleep-related movement disorders19. Thus, it was reasonable to hypothesize that PLMS might be associated with tinnitus.

Currently, polysomnography is the gold standard and only clinically acceptable means of quantifying PLMS, which presented with repetitive stereotyped movements, typically in the lower limbs, during sleep. PLMS could disrupt sleep and result in daytime sleepiness20. PLMS have been proposed to be associated with increased risk of heart diseases and/or cardiovascular events21. Meta-analysis showed that, compared to subjects without PLMS,
there were significantly higher co-morbidity rates of coronary artery disease and cardiovascular diseases (CVD), but not acute myocardial infarction, in subjects with PLMS\(^2\). Meanwhile, these PLMS-related complications and/or sequelae might also contribute to tinnitus formation\(^2,3,5–7\).

To our knowledge, the association of PLMS and tinnitus was never reported till now. Therefore, the aim of this study was to examine the association of PLMS and chronic tinnitus in humans.

**Methods**

From Nov. 2011 to Jun 2017, clinical and overnight polysomnographic data of 2849 adult patients with sleep disturbances at Dalin Tzu Chi Hospital were retrospectively collected. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Research Ethics Committee of Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (No. B10604018). Informed written consent was waived because the study was a retrospective data analysis.

Clinical data including age, sex, subjective hearing loss, insomnia, and Parkinson's disease were acquired before overnight PSG examination. Subjective hearing loss was graded as “no” and “yes” in response to a question of “Do you have difficult hearing other people clearly in daily activities”. Insomnia was graded into five grades as “no”, “rare”, “sometimes”, “often”, and “usually”. PLMS was treated by two methods. First, PLMS was originally a continuous variable (/h). Second, PLMS was graded into four grades as “no”, “mild (>5/h but <25/h)”, “moderate (>25/h but <50/h)”, and “severe (>50/h)”. And, chronic tinnitus was graded as “no” and “yes”, and regarded as non-tinnitus group and tinnitus group, respectively.

**Statistical analysis.** Student's t-test was used to test the difference of continuous variables between non-tinnitus and tinnitus group. Pearson's Chi-Square test was used to test the association of PLMS with different severity and chronic tinnitus. Multivariate logistic regression was used to test the association of PLMS (continuous values) and chronic tinnitus. All analyses were performed using STATA 10.0 software (Stata Corp, College Station, Texas). \(P < 0.05\) was considered to be significant.

**Results**

There were 989 females and 1860 males in this study. The mean age was 50.6 years old (standard deviation, SD = 13.3, range=18–91) for all subjects. Among that, there were 1886 subjects without chronic tinnitus and 963 subjects with chronic tinnitus in this study.

Table 1 showed the basic characteristics of non-tinnitus and tinnitus groups. Compared to non-tinnitus group, tinnitus group had significantly higher age (mean = 54.2 years old, SD = 12.2 versus mean = 48.8 years old, SD = 13.5, \(p < 0.0001\)), proportion of females (39.4% versus 32.3%, \(p < 0.001\)), and prevalence of subjective hearing loss (37.7% versus 5.6%, \(p < 0.001\) and insomnia (87.8% versus 76.5%, \(p < 0.001\)). But, PLMS (mean = 1.1/h, SD = 3.4 versus mean = 1.0/h, SD = 3.5, \(p = 0.4557\)) and prevalence of Parkinson's disease (0.9% versus 0.8%, \(p = 0.808\)) were not significantly different between non-tinnitus and tinnitus groups.

Table 2 showed the association of PLMS with different severity and chronic tinnitus. The severity of PLMS was not significantly associated with chronic tinnitus (\(p = 0.639\) by Pearson’s Chi-Square test).

Table 3 showed the multivariate logistic regression analysis for the association of PLMS on chronic tinnitus with adjustment of other variables. The results showed that PLMS was not significantly associated with chronic tinnitus after adjusting for age, sex, subjective hearing loss, Parkinson’s disease, and insomnia.

**Discussion**

This retrospective study based on clinical and PSG data showed that PLMS, one kind of sleep disturbances, was not significantly associated with chronic tinnitus before and after adjusting other variables. This clinical finding did not support the expectation based on the dopaminergic system dysfunction for both of PLMS and chronic tinnitus\(^5,6,8–10\). Also, although PLMS-related complications and/or sequelae might contribute to tinnitus\(^5,6,8–10\), current results did not show positive correlation between PLMS and chronic tinnitus in humans at all.

In this study, we showed that older age, male subjects, hearing loss, and insomnia had higher risk for having chronic tinnitus. These findings were very reasonable and expectative. Talking about the relationship of tinnitus and sleep disturbance, loud tinnitus was associated with 2.8-fold and 3.3-fold increases in the odds ratios of

| Table 1. The characteristics of non-tinnitus and tinnitus groups. |
| --- | --- | --- |
| **Age (y/o)** | Non-tinnitus (n = 1886) | Tinnitus (n = 963) | \(p\) |
| 48.8 (13.5) | 54.2 (12.2) | <0.0001 |
| **Sex (F/M, %)** | 32.3/67.7 | 39.4/60.6 | <0.001 |
| **Paroxysmal limb movement (/h)** | 1.0 (3.5) | 1.1 (3.4) | 0.4557 |
| **Subjective hearing loss (No/Yes, %)** | 94.4/5.6 | 62.3/37.7 | <0.001 |
| **Parkinson’s disease (No/Yes, %)** | 99.2/0.8 | 99.1/0.9 | 0.808 |
| **Insomnia (grade, %)** | | | <0.001 |
| No | 23.5 | 12.2 |
| Rare | 25.7 | 14.2 |
| Sometimes | 25.4 | 25.8 |
| Often | 16.9 | 31.2 |
| Usually | 8.5 | 16.6 |

| Table 2 showed the association of PLMS with different severity and chronic tinnitus. |
| --- | --- | --- |
| **Severity of PLMS** | Non-tinnitus (n = 1886) | Tinnitus (n = 963) | \(p\) |
| No | 13.3 (3.5) | <0.001 |
| Rare | 39.4 (3.5) |
| Sometimes | 25.4 (3.4) |
| Often | 16.9 (3.0) |
| Usually | 8.5 (3.0) |
insomnia in men and women, respectively\textsuperscript{23}. Difficulty in initiating and maintaining sleep were related with tinnitus\textsuperscript{23}. Furthermore, our previous studies showed that sleep disturbance, especially for sleep apnea, could increase the risk of tinnitus\textsuperscript{2}. Thus, many people got trapped in a vicious cycle of sleep disturbances and tinnitus. Even though, it is still unclear whether sleep-related movement disorders, such as PLMS, was associated with tinnitus or not till now.

In the aspect of dopaminergic system Trotti (2017), reported that dopamine agonists could reduce the severity of PLMS\textsuperscript{19}. On the other hand, the results about tinnitus-related dopaminergic pathway dysfunction varied. For example, sulpiride, an agonists and antagonists of dopamine receptors (DRs) can reduce tinnitus\textsuperscript{18}. Pramipexole, an agonist of DR2/3, could reduce tinnitus associated with presbycusis\textsuperscript{24}. Bupropion, a dopamine reuptake inhibitor, did not enhance the treatment effect of repetitive transcranial magnetic stimulation of the temporal cortex for tinnitus\textsuperscript{25}. Salicylate-induced tinnitus might be associated with increasing mRNA expressions of DR1A gene in the cochlear, brainstem and inferior colliculus, hippocampus and parahippocampus, and temporal lobes, but not in the frontal lobes\textsuperscript{15}. So, it seemed that DR2/3 activation would suppress tinnitus, whereas DR1 activation would enhance tinnitus.

As for sleep-related movement disorders, although restless legs syndrome (RLS), PLMS, and periodic limb movement disorder (PLMD) were different by definition\textsuperscript{26}, their treatments were very similar\textsuperscript{27}. RLS might be associated with several conditions, including growing pains, kidney diseases, migraine, diabetes mellitus, epilepsy, rheumatologic disorders, CVD, liver and gastrointestinal disorders, and neuropsychiatric disorders [e.g., attention deficit hyperactivity disorder (ADHD), depression, and conduct disorder\textsuperscript{28}]. The prevalence of associated diagnoses of PLMS in pediatric population was 46.8% for OSA, 13% for ADHD, 9.1% for migraine, 9.1% for seizure, 6.5% for autism spectrum disorders, 9.1% for narcolepsy, and 96.6% for decreased serum ferritin\textsuperscript{29}.

RLS and/or PLMS might also increase cardiovascular risk by increasing heart rate and blood pressure, resulting in sleep fragmentation and sleep deprivation, which produced adverse consequences for neural, metabolic, oxidative, inflammatory, and vascular systems, and iron deficiency, which was also a risk for CVD\textsuperscript{30}. Also, PLMS are found in 30% of patients suffering from OSA\textsuperscript{31}. Patients with PLMS had higher artery stiffness than their controls and those with moderate/severe OSA did. And, a possible additive effect of OSA and PLMS on arterial stiffness was found\textsuperscript{32}. Thus, PLMS might increase the risk of CVD directly and/or indirectly via its comorbid diseases, including OSA as our previous study shown\textsuperscript{2}.

This finding did not against the use of DR agonists and/or antagonists on chronic tinnitus clinically. We still supposed that some DR agonists might be helpful for patients with PLMS and/or chronic tinnitus by reducing the chances of PLMS-related sequelae. But, it needs more studies to confirm our hypothesis in the future.

### Conclusion

This clinical study found that PLMS was not associated with chronic tinnitus in humans, even though possible similar pathophysiology was established in both symptoms.

Received: 11 July 2019; Accepted: 18 March 2020; Published online: 06 April 2020

### References

1. Kim, H. J. \textit{et al}. Analysis of the prevalence and associated risk factors of tinnitus in adults. \textit{PLoS One} \textbf{10}, e0127578 (2015).

2. Koo, M. & Hwang, J. H. Risk of tinnitus in patients with sleep apnea: a nationwide, population-based case-control study. \textit{Laryngoscope} \textbf{127}, 2171–2175 (2017).
3. Hwang, J. H., Tsai, S. I., Liu, T. C., Chen, Y. C. & Lai, I. T. Association of tinnitus and other cochlear disorders with a history of migraine. JAMA Otolaryngology Head & Neck Surgery 144, 712–717 (2018).

4. Chen, Y. C., Tsai, S. J., Chen, J. C. & Hwang, J. H. Risks of tinnitus, sensorineural hearing impairment, and sudden deafness in patients with non-migraine headache. PLoS One 14(9), e0222041 (2019).

5. Miguel, G. S., Varemcuk, K., Roth, T. & Peterson, E. The effect of insomnia on tinnitus. Ann. Otol. Rhinol. Laryngol. 123, 696–700 (2014).

6. Chen, J. C., Koo, M. & Hwang, J. H. Tinnitus is associated with a higher risk of benign brain tumors: A nationwide, population-based secondary cohort study of young and middle-aged adults. Neuroepidemiology 49, 174–178 (2017).

7. Huang, Y. S., Koo, M., Chen, J. C. & Hwang, J. H. The association between tinnitus and the risk of ischemic cerebrovascular disease in young and middle-aged patients: a secondary case-control analysis of a nationwide, population-based health claims database. PLoS One 12(11), e0187474 (2017).

8. Issa, M., Bisconti, S., Kovalien, I., Kileny, P. & Basura, G. J. Human auditory and adjacent non auditory cerebral cortices are hypermetabolic in tinnitus as measured by functional near-infrared spectroscopy (fNIRS). Neural Plast. 7453149 (2016).

9. Chan, Y. C., Wang, M. F. & Hwang, J. H. Effects of Spirulina on GABA receptor gene expression in salicylate-induced tinnitus. International Tinnitus Journal 22, 84–88 (2017).

10. Hwang, J. H., Chen, J. C., Yang, S. Y., Wang, M. F. & Chan, Y. C. Expression of TNF-alpha and IL-1beta genes in the cochlea and midbrain in salicylate-induced tinnitus. J. Neuroinflammation 8, 30–36 (2011).

11. Hwang, J. H., Chen, J. C. & Chan, Y. C. Effects of C-phycocyanin and Spirulina on salicylate-induced tinnitus, expression of NMDA receptor and inflammatory genes. PLoS One 8(3), e58215 (2013).

12. Hwang, J. H., Chang, N. C., Chen, J. C. & Chan, Y. C. Expression of antioxidant genes in the mouse cochlea and brain in salicylate-induced tinnitus and effect of treatment with Spirulina platensis water extract. Audiol. Neurootol. 20, 322–329 (2015).

13. Hwang, J. H., Huang, C. W., Lu, Y. C., Yang, W. S. & Liu, T. C. Effects of tumor necrosis factor blocker on salicylate-induced tinnitus in mice. International Tinnitus. Journal 21, 24–29 (2017).

14. Hwang, J. H. et al. Expression of COX-2 and NMDA receptor genes at the cochlea and midbrain in salicylate-induced tinnitus. Laryngoscope 121, 361–364 (2011).

15. Zheng, T., Baek, J. H., Smith, P. F. & Darlington, C. L. Cannabinoid receptor down-regulation in the ventral cochlear nucleus in a salicylate model of tinnitus. Hearing Research 228(1–2), 105–111 (2007).

16. Hwang, J. H. & Chan, Y. C. Expressions of ion co-transporter genes in salicylate-induced tinnitus and treatment effects with spirulina. BMC Neurology 16, 159–164 (2016).

17. Hwang, J. H. & Chan, Y. C. Expression of dopamine receptor 1A and cannabinoid receptor 1 genes in the cochlea and brain after salicylate-induced tinnitus. ORL: J. Otorhinolaryngol Relat. Spec. 78, 268–273 (2016).

18. Lopez-Gonzalez, M. A., Santiago, A. M. & Esteban-Ortega, F. Sulpiride and melatonin decrease tinnitus perception modulating the auditoilmic dopaminergic pathway. J. Otolaryngol. 36, 213–219 (2007).

19. Trotti, L. M. Restless legs syndrome and sleep-related movement disorders. Continuum. (Minneap Minn) 23, 1005–1016 (2017).

20. Plante, D. T. Leg actigraphy to quantify periodic limb movements of sleep: a systematic review and meta-analysis. Sleep Med. Rev. 18, 425–434 (2014).

21. Kondierska, T., Kanra, M., Murray, B. J. & Boulou, M. I. Incident cardiovascular events and death in individuals with restless legs syndrome or periodic limb movements in sleep: A Systematic Review. Sleep 40(3) (2017).

22. Huang, T. C. et al. Periodic limb movements during sleep are associated with cardiovascular diseases: A systematic review and meta-analysis. J. Sleep Res. 28(3), e12720 (2019).

23. Izuha, K. et al. Association between tinnitus and sleep disorders in the general Japanese population. Ann. Otol. Rhinol. Laryngol. 122, 701–706 (2013).

24. Sziklai, I., Szilvássy, J. & Szilvássy, Z. Tinnitus control by dopamine agonist pramipexole in presbycusis patients: a randomized, placebo-controlled, double-blind study. Laryngoscope 121, 888–893 (2011).

25. Kleinjung, T. et al. Repetitive transcranial magnetic stimulation for tinnitus treatment: no enhancement by the dopamine and noradrenaline reuptake inhibitor bupropion. Brain Stimul. 4, 65–70 (2011).

26. Salas, R. E., Rasquinha, R. & Gamaldo, C. E. All the wrong moves: a clinical review of restless legs syndrome, periodic limb movements of sleep and wake, and periodic limb movement disorder. Clin. Chest. Med. 31, 383–395 (2010).

27. Aurora, R. N. et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults—an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep 35, 1039–1062 (2012).

28. Angriman, M., Cortese, S. & Bruni, O. Somatic and neuropsychiatric comorbidities in pediatric restless legs syndrome: A systematic review of the literature. Sleep Med. Rev. 34, 34–45 (2017).

29. Bokkala, S. et al. Correlates of periodic limb movements of sleep in the pediatric population. Pediatr. Neurol. 39, 33–39 (2008).

30. Gottlieb, D. J., Somers, V. K., Punjabi, N. M. & Winkelman, J. W. Restless legs syndrome and cardiovascular disease: a research roadmap. Sleep Med. 31, 10–17 (2017).

31. Mwenge, G. B., Rougui, J. & Rodenstein, D. Effect of changes in periodic limb movements under CPAP on adherence and long term compliance in obstructive sleep apnea. Acta. Clin. Belg. 73, 191–198 (2018).

32. Drakatos, P. et al. Derived arterial stiffness is increased in patients with obstructive sleep apnea and periodic limb movements during sleep. J Clin Sleep Med 12, 195–202 (2016).

Author contributions
S.W.H. and S.R.H.: data acquisition and wrote the initial manuscript. Y.C.C.: statistical analysis and interpretation of data. J.H.H.: conception and design of study, analysis and interpretation of data, final approval of the version to be published.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to J.-H.H.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
